Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 3,200 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $5.00, for a total value of $16,000.00. Following the sale, the chief executive officer now directly owns 15,075,424 shares in the company, valued at $75,377,120. This trade represents a 0.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
David Zaccardelli also recently made the following trade(s):
- On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total transaction of $495,428.88.
- On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $116,200.00.
- On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $12,000.00.
- On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
- On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $205,369.44.
- On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $21,024.00.
- On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $70.08.
- On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
- On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92.
Verona Pharma Trading Down 1.3 %
Amazon coin set to soar 25X – starting December 16th?
From True Market Insiders | Ad
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon.
And one team of crypto experts has identified it as the most promising crypto of 2024.
You can see all of the details surrounding the #1 Crypto of 2024
>3-Cent Amazon Coin<
NASDAQ VRNA opened at $39.11 on Tuesday. The stock has a 50-day moving average of $34.85 and a 200-day moving average of $25.61. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma plc has a 1-year low of $11.39 and a 1-year high of $40.76. The firm has a market cap of $3.13 billion, a PE ratio of -20.37 and a beta of 0.46.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to analysts' expectations of $2.31 million. During the same period in the prior year, the firm earned ($0.18) EPS. As a group, sell-side analysts forecast that Verona Pharma plc will post -2.11 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on VRNA shares. Truist Financial lifted their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. Wells Fargo & Company upped their price objective on Verona Pharma from $50.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. HC Wainwright raised their price objective on Verona Pharma from $36.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity Group boosted their target price on Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $43.83.
View Our Latest Research Report on VRNA
Institutional Investors Weigh In On Verona Pharma
Institutional investors have recently added to or reduced their stakes in the company. CWM LLC purchased a new position in shares of Verona Pharma in the second quarter valued at about $29,000. EMC Capital Management purchased a new position in Verona Pharma during the 2nd quarter valued at about $38,000. GAMMA Investing LLC increased its holdings in Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock valued at $38,000 after purchasing an additional 553 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock valued at $75,000 after purchasing an additional 529 shares during the last quarter. Finally, Legato Capital Management LLC purchased a new stake in Verona Pharma in the 2nd quarter worth approximately $154,000. Hedge funds and other institutional investors own 85.88% of the company's stock.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
